Sarcopenia Clinics Is It Time for a New Geriatric Subspecialty Abstract Sarcopenia has emerged as one of the most important age related musculoskeletal disorders in contemporary geriatric medicine. Characterized by progressive loss of skeletal muscle mass, reduced muscle strength, and impaired physical performance, sarcopenia contributes significantly to frailty, falls,
Tag: Sarcopenia
Muscle Aging and Sarcopenia: Are Senolytics the Missing Piece?
Muscle Aging and Sarcopenia: Are Senolytics the Missing Piece? Abstract Age-related muscle loss, known as sarcopenia, affects millions of older adults worldwide. This condition leads to decreased strength, mobility, and independence while increasing fall risk and mortality. Traditional treatments focus on exercise and
Hidden Crisis: Why Sarcopenia Treatment Matters More Than You Think in 2025
Hidden Crisis: Why Sarcopenia Treatment Matters More Than You Think in 2025 Introduction Sarcopenia treatment represents a critical healthcare priority as the prevalence of this age-related muscle wasting condition reaches alarming levels. The economic burden of sarcopenia in the United States was approximately
Sarcopenia Screening For Mortality In Oncology Patients
Sarcopenia Screening For Mortality In Oncology Patients Overview This study evaluated the effectiveness of a sarcopenia screening test in predicting mortality among cancer inpatients. Conducted over five months, 82 patients admitted to an oncology ward in southern Taiwan were assessed and followed for three years. Each participant underwent a comprehensive
Sarcopenia And Chronic Kidney Disease
Sarcopenia And Chronic Kidney Disease Overview Sarcopenia and frailty are common conditions among people with chronic kidney disease (CKD), which may further enhance their risk of developing adverse health complications. Only a few studies have demonstrated the association between sarcopenia, frailty and chronic kidney disease in patients who are not on dialysis.
Osteopenia predicts outcomes in pancreatic cancer
Osteopenia predicts outcomes in pancreatic cancer Study Background Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer deaths in the United States and is projected to become the second by 2030. The unfavorable prognosis of PDAC can be attributed to late diagnosis, poor metabolic status, and the resistance of cancer
skeletal muscle mass and cancer patient quality of life: a meta-analysis
skeletal muscle mass and cancer patient quality of life: a meta-analysis Loss of skeletal muscle mass (sarcopenia), is a widely prevalent problem among cancer patients with incidence ranging from 11 to 74%. Low skeletal muscle mass at baseline is predictive of poor cancer outcomes such as decreased overall survival, increased risk
